ACS chemical neuroscience molecule spotlight on savella

Research output: Contribution to journalShort surveypeer-review


Savella (milnacipran), a selective serotonin and noradrenaline reuptake inhibitor, was approved by the FDA on January 14th, 2009, for the treatment of fibromyalgia.

Original languageEnglish (US)
Pages (from-to)345
Number of pages1
JournalACS Chemical Neuroscience
Issue number5
StatePublished - May 19 2010
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology


Dive into the research topics of 'ACS chemical neuroscience molecule spotlight on savella'. Together they form a unique fingerprint.

Cite this